Christopher J Child1, Daniel Conroy2, Alan G Zimmermann2, Whitney W Woodmansee2, Eva Marie Erfurth2, Leslie L Robison2. 1. Lilly Research LaboratoriesErl Wood Manor, Windlesham, Surrey GU20 6PH, UKinVentiv Health ClinicalBurlington, Massachusetts 01803 USALilly Research LaboratoriesIndianapolis, Indiana 46285, USADivision of EndocrinologyDiabetes and Hypertension, Brigham and Women's Hospital/Harvard Medical School, Boston, Massachusetts 02115, USADepartment of EndocrinologySkånes University Hospital, Lund 221 85, SwedenDepartment of Epidemiology and Cancer ControlSt Jude Children's Research Hospital, Memphis, Tennessee 38105-3678, USA cjc@lilly.com. 2. Lilly Research LaboratoriesErl Wood Manor, Windlesham, Surrey GU20 6PH, UKinVentiv Health ClinicalBurlington, Massachusetts 01803 USALilly Research LaboratoriesIndianapolis, Indiana 46285, USADivision of EndocrinologyDiabetes and Hypertension, Brigham and Women's Hospital/Harvard Medical School, Boston, Massachusetts 02115, USADepartment of EndocrinologySkånes University Hospital, Lund 221 85, SwedenDepartment of Epidemiology and Cancer ControlSt Jude Children's Research Hospital, Memphis, Tennessee 38105-3678, USA.
Abstract
OBJECTIVE: Speculation remains that GH treatment is associated with increased neoplasia risk. Studies in GH-treated childhood cancer survivors suggested higher rates of second neoplasms, while cancer risk data for GH-treated and untreated hypopituitary adults have been variable. We present primary cancer risk data from the Hypopituitary Control and Complications Study (HypoCCS) with a focus on specific cancers, and assessment of recurrence rates for pituitary adenomas (PA) and craniopharyngiomas (CP). DESIGN: Incident neoplasms during HypoCCS were evaluated in 8418 GH-treated vs 1268 untreated patients for primary malignancies, 3668 GH-treated vs 720 untreated patients with PA history, and 956 GH-treated vs 102 untreated patients with CP history. METHODS: Using population cancer rates, standardised incidence ratios (SIRs) were calculated for all primary cancers, breast, prostate, and colorectal cancers. Neoplasm rates in GH-treated vs untreated patients were analysed after propensity score adjustment of baseline treatment group imbalances. RESULTS: During mean follow-up of 4.8 years, 225 primary cancers were identified in GH-treated patients, with SIR of 0.82 (95% CI 0.71-0.93). SIRs (95% CI) for GH-treated patients were 0.59 (0.36-0.90) for breast, 0.80 (0.57-1.10) for prostate, and 0.62 (0.38-0.96) for colorectal cancers. Cancer risk was not statistically different between GH-treated and untreated patients (relative risk (RR)=1.00 (95% CI 0.70-1.41), P=0.98). Adjusted RR for recurrence was 0.91 (0.68-1.22), P=0.53 for PA and 1.32 (0.53-3.31), P=0.55 for CP. CONCLUSIONS: There was no increased risk for all-site cancers: breast, prostate or colorectal primary cancers in GH-treated patients during HypoCCS. GH treatment did not increase the risk of PA and CP recurrences.
OBJECTIVE: Speculation remains that GH treatment is associated with increased neoplasia risk. Studies in GH-treated childhood cancer survivors suggested higher rates of second neoplasms, while cancer risk data for GH-treated and untreated hypopituitary adults have been variable. We present primary cancer risk data from the Hypopituitary Control and Complications Study (HypoCCS) with a focus on specific cancers, and assessment of recurrence rates for pituitary adenomas (PA) and craniopharyngiomas (CP). DESIGN: Incident neoplasms during HypoCCS were evaluated in 8418 GH-treated vs 1268 untreated patients for primary malignancies, 3668 GH-treated vs 720 untreated patients with PA history, and 956 GH-treated vs 102 untreated patients with CP history. METHODS: Using population cancer rates, standardised incidence ratios (SIRs) were calculated for all primary cancers, breast, prostate, and colorectal cancers. Neoplasm rates in GH-treated vs untreated patients were analysed after propensity score adjustment of baseline treatment group imbalances. RESULTS: During mean follow-up of 4.8 years, 225 primary cancers were identified in GH-treated patients, with SIR of 0.82 (95% CI 0.71-0.93). SIRs (95% CI) for GH-treated patients were 0.59 (0.36-0.90) for breast, 0.80 (0.57-1.10) for prostate, and 0.62 (0.38-0.96) for colorectal cancers. Cancer risk was not statistically different between GH-treated and untreated patients (relative risk (RR)=1.00 (95% CI 0.70-1.41), P=0.98). Adjusted RR for recurrence was 0.91 (0.68-1.22), P=0.53 for PA and 1.32 (0.53-3.31), P=0.55 for CP. CONCLUSIONS: There was no increased risk for all-site cancers: breast, prostate or colorectal primary cancers in GH-treated patients during HypoCCS. GH treatment did not increase the risk of PA and CP recurrences.
Authors: Sina Jasim; Fares Alahdab; Ahmed T Ahmed; Shrikant U Tamhane; Anu Sharma; Diane Donegan; Todd B Nippoldt; M Hassan Murad Journal: Endocrine Date: 2016-11-04 Impact factor: 3.633
Authors: Susan R Rose; Vincent E Horne; Jonathan Howell; Sarah A Lawson; Meilan M Rutter; Gylynthia E Trotman; Sarah D Corathers Journal: Nat Rev Endocrinol Date: 2016-04-01 Impact factor: 43.330
Authors: Gudmundur Johannsson; Philippe Touraine; Ulla Feldt-Rasmussen; Antonio Pico; Greisa Vila; Anders F Mattsson; Martin Carlsson; Márta Korbonits; André P van Beek; Michael P Wajnrajch; Roy Gomez; Kevin C J Yuen Journal: J Clin Endocrinol Metab Date: 2022-06-16 Impact factor: 6.134
Authors: Margaret C S Boguszewski; Cesar L Boguszewski; Wassim Chemaitilly; Laurie E Cohen; Judith Gebauer; Claire Higham; Andrew R Hoffman; Michel Polak; Kevin C J Yuen; Nathalie Alos; Zoltan Antal; Martin Bidlingmaier; Beverley M K Biller; George Brabant; Catherine S Y Choong; Stefano Cianfarani; Peter E Clayton; Regis Coutant; Adriane A Cardoso-Demartini; Alberto Fernandez; Adda Grimberg; Kolbeinn Guðmundsson; Jaime Guevara-Aguirre; Ken K Y Ho; Reiko Horikawa; Andrea M Isidori; Jens Otto Lunde Jørgensen; Peter Kamenicky; Niki Karavitaki; John J Kopchick; Maya Lodish; Xiaoping Luo; Ann I McCormack; Lillian Meacham; Shlomo Melmed; Sogol Mostoufi Moab; Hermann L Müller; Sebastian J C M M Neggers; Manoel H Aguiar Oliveira; Keiichi Ozono; Patricia A Pennisi; Vera Popovic; Sally Radovick; Lars Savendahl; Philippe Touraine; Hanneke M van Santen; Gudmundur Johannsson Journal: Eur J Endocrinol Date: 2022-04-21 Impact factor: 6.558
Authors: Max Esefeld; Antoni Pastor; Rafael de la Torre; Osquel Barroso; Reid Aikin; Hina Sarwath; Rudolf Engelke; Frank Schmidt; Karsten Suhre Journal: J Endocr Soc Date: 2021-11-02
Authors: Victor Caz; Marcos Elvira; Maria Tabernero; Antonio G Grande; Bricia Lopez-Plaza; Enrique de Miguel; Carlota Largo; Monica Santamaria Journal: PLoS One Date: 2015-12-15 Impact factor: 3.240